≥99% β-NMNTier 2
Evidence. Several RCTs (250–900 mg/day) raise blood NAD+; improved walking distance and insulin sensitivity in subsets; FDA Sept 29 2025 letters declare NMN not excluded from the supplement definition.
Cautions. Flushing rare; long-term outcome data absent.
nutraingredients.com/Article/2025/09/30/f…venable.com/insights/publications/2025/10…nutraingredients.com/Article/2025/12/09/f…
≥99% urolithin ATier 2
Evidence. ATLAS RCT (n=88, 500/1,000 mg × 4 mo): hamstring strength +12%/+9.8% vs placebo, primary endpoint (peak power) null; older-adult RCT (1,000 mg) improved muscle endurance, 6MWT primary null.
Cautions. Well tolerated; null primary endpoints noted.
pmc.ncbi.nlm.nih.gov/articles/PMC9133463/jamanetwork.com/journals/jamanetworkopen/…
Wheat germ extract standardized to spermidineTier 3
Evidence. SmartAge RCT (n=100, 1.2 mg/day) improved memory performance trend; epidemiology links dietary spermidine with lower mortality; 2 mg/day = 1,300 mg extract.
Cautions. Contains wheat (gluten) — label allergen.
spermidinelife.com/en/products/spermidine…pubmed.ncbi.nlm.nih.gov/?term=spermidine+…
Ca-AKG ≥98%Tier 3
Evidence. Rejuvant retrospective (n=42): −8 yr TruAge after 7 mo; 2025 cross-sectional cohort (n=4,260) found delayed-release CaAKG the only compound of 84 associated with lower biological age. No RCT on hard endpoints.
Cautions. Well tolerated; calcium load ~100 mg.
pmc.ncbi.nlm.nih.gov/articles/PMC8660611/onlinelibrary.wiley.com/doi/10.1111/acel.70517
Fisetin from Rhus succedaneaTier 3
Evidence. Strong preclinical senolytic data; Mayo/PAD RCTs (FIRST, NCT06399809) ongoing; low-dose triple-blind RCT protocol published 2026.
Cautions. Low oral bioavailability (liposomal form chosen); none significant.
clinicaltrials.gov/study/NCT06399809pubmed.ncbi.nlm.nih.gov/42633989/
Quercetin–sunflower lecithin phytosome (≥40% quercetin), up to 20× absorptionTier 3
Evidence. PK superiority (20-fold); RCTs on exercise recovery/URTI symptoms at 250–500 mg; senolytic pairing with fisetin is preclinical.
Cautions. CYP3A4/P-gp interaction potential at high doses.
indena.com/us/products/see-through-scienc…
Fermentation-derived L-ergothioneineTier 3
Evidence. Independent RCT (n=147, 10/25 mg): primary memory endpoint null, secondary cognitive gains; MCI pilot (n=19, 25 mg 3×/wk); liver open-label at 60 mg.
Cautions. Well tolerated; primary endpoint null noted.
geneiii.com/products/l-ergothioneine-capsulespubmed.ncbi.nlm.nih.gov/39544014/
Proprietary polyphenol blend, 95 mg studiedTier 3
Evidence. 6-month open study at 95 mg 1–2×/day reported telomere-length change; NO placebo arm (CSPI critique) — score capped.
Cautions. None reported; evidence quality flag (H-note: no placebo).
certifiednutra.com/ingredient-solutions/t…cspi.org/daily/dietary-supplements/what-d…
Anthocyanin extract standardized to C3GTier 3
Evidence. Anthocyanin RCTs (320 mg/day) improved HDL/LDL and endothelial markers; C3G-specific human data limited.
Cautions. None significant.
pubmed.ncbi.nlm.nih.gov/?term=anthocyanin…
KPE 5% polymethoxyflavonesTier 3
Evidence. Small RCTs (100–150 mg/day): improved physical fitness/grip in older adults, hand-grip and NO markers; AMPK/SIRT activation preclinical.
Cautions. None significant.
pubmed.ncbi.nlm.nih.gov/?term=Kaempferia+…
99% trans-pterostilbeneTier 3
Evidence. Human RCT (125 mg b.i.d.): BP reduction; LDL increase at high dose (H-note); superior absorption vs resveratrol.
Cautions. Raised LDL at 250 mg/day in one RCT — kept to 50 mg.
api.ods.od.nih.gov/dsld/s3/pdf/181999.pdfpubmed.ncbi.nlm.nih.gov/?term=pterostilbe…